Literature DB >> 22581873

The cost of managing genital warts in the UK.

T Lanitis1, S Carroll, C O'Mahony, F Charman, J M Khalid, V Griffiths, R E Brown.   

Abstract

The national cost of managing genital warts (GWs) in the UK has not been fully estimated, yet is required to inform decisions on vaccination against human papillomavirus. This study estimated the 2010 UK costs based on secondary genitourinary (GU) medicine clinic data from the Health Protection Agency (HPA) and primary care data from the Health Improvement Network database. Extrapolating data to 2010 resulted in 173,077 GU medicine clinic and 16,782 primary care GW episodes. Using treatment patterns obtained from key opinion leaders and tariffs from National Health Service Payment by Results (NHS PbR), the national costs were estimated at £52.4 million: £276 per treated GW episode.

Entities:  

Mesh:

Year:  2012        PMID: 22581873     DOI: 10.1258/ijsa.2011.011218

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  3 in total

Review 1.  Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.

Authors:  Luciano Mariani; Patrizia Vici; Barbara Suligoi; Giovanni Checcucci-Lisi; Rosybel Drury
Journal:  Adv Ther       Date:  2015-01-27       Impact factor: 3.845

2.  Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata.

Authors:  Matthew G Hawkins; David M Winder; Siolian L R Ball; Katie Vaughan; Christopher Sonnex; Margaret A Stanley; Jane C Sterling; Peter K C Goon
Journal:  Virol J       Date:  2013-05-01       Impact factor: 4.099

3.  Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.

Authors:  Anne Szarewski; S Rachel Skinner; Suzanne M Garland; Barbara Romanowski; Tino F Schwarz; Dan Apter; Song-Nan Chow; Jorma Paavonen; M Rowena Del Rosario-Raymundo; Julio C Teixeira; Newton S De Carvalho; Maria Castro-Sanchez; Xavier Castellsagué; Willy A J Poppe; Philippe De Sutter; Warner Huh; Archana Chatterjee; Wiebren A Tjalma; Ronald T Ackerman; Mark Martens; Kim A Papp; Jose Bajo-Arenas; Diane M Harper; Aureli Torné; Marie-Pierre David; Frank Struyf; Matti Lehtinen; Gary Dubin
Journal:  J Infect Dis       Date:  2013-11-01       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.